Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Boni

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for NeuroblastomaA Garaventa, B De Bernardi, C Pianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 childrenG P Tonini, L Boni, A Pession, et al.
British Journal of Cancer|January 14, 2012
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)C Boni, M Tiseo, L Boni, et al.
ESMO Open|January 5, 2021
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)B Pellegrino, L Cavanna, D Boggiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 3, 2014
VEGF-A clinical significance in gastric cancers: immunohistochemical analysis of a wide Italian cohortE Lastraioli, L Boni, M R Romoli, et al.
British Journal of Cancer|February 27, 2015
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinomaE Lastraioli, G Perrone, A Sette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) CT/PETA Gennari, E Brain, A De Censi, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for NeuroblastomaA Garaventa, B De Bernardi, C Pianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 childrenG P Tonini, L Boni, A Pession, et al.
British Journal of Cancer|January 14, 2012
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)C Boni, M Tiseo, L Boni, et al.
ESMO Open|January 5, 2021
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)B Pellegrino, L Cavanna, D Boggiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 3, 2014
VEGF-A clinical significance in gastric cancers: immunohistochemical analysis of a wide Italian cohortE Lastraioli, L Boni, M R Romoli, et al.
British Journal of Cancer|February 27, 2015
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinomaE Lastraioli, G Perrone, A Sette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) CT/PETA Gennari, E Brain, A De Censi, et al.
Pageof 18